Clinical and pathological characteristics
| Characteristics . | MGZL . | PMBL10 . | 2-tailed P . | ||
|---|---|---|---|---|---|
| No. . | % . | No. . | % . | ||
| Total patients | 24 | 51 | |||
| Male gender | 15 | 63 | 21 | 41 | .14 |
| Age, years | .61 | ||||
| Median | 33 | 30 | |||
| Range | 14-59 | 19-52 | |||
| Bulky tumor ≥10 cm | 11 | 46 | 33 | 65 | .14 |
| Range | 1.3-20 | 5-18 | |||
| Stage IV disease | 3 | 13 | 15 | 29 | .15 |
| LDH >normal | 12 | 50 | 40 | 78 | .017 |
| Extranodal site | 6 | 25 | 27 | 53 | .027 |
| Pleural or pericardial effusion | 5 | 21 | 28 | 55 | .006 |
| ALC cells per µl | 1.01 (0.24-2.15) | .78 | |||
| Median | 0.88 | 1.01 | |||
| Range | 0.3-2.88 | 0.24-2.15 | |||
| Predominant tumor morphology | |||||
| PMBL-like | 8 | 33 | NA | ||
| NSHL-like | 15 | 63 | NA | ||
| Composite (BMBL and NSHL) | 1 | 4 | NA | ||
| IHC | |||||
| CD20+ (malignant cells) | |||||
| First to fourth quartiles | 24/24 | 100 | 51/51 | 100 | 1.0 |
| ≥Fourth quartile | 17/24 | 71 | 51/51 | 100 | <.0001 |
| CD30+ (malignant cells) | 24/24 | 100 | 30/44 | 68 | .001 |
| CD15+ (malignant cells) | |||||
| ≥First quartile | 13/24 | 54 | 2/34 | 6 | <.0001 |
| BCL-6-positive (malignant cells) | 13/15 | 86 | 33/37 | 89 | 1.0 |
| DC-SIGN-positive (bystander cells) | |||||
| ≥1+ staining | 10/19 | 53 | 12/35 | 34 | .25 |
| CD68+ (bystander cells) | |||||
| ≥ 5% staining | 16/16 | 100 | 26/28 | 93 | 1.0 |
| Characteristics . | MGZL . | PMBL10 . | 2-tailed P . | ||
|---|---|---|---|---|---|
| No. . | % . | No. . | % . | ||
| Total patients | 24 | 51 | |||
| Male gender | 15 | 63 | 21 | 41 | .14 |
| Age, years | .61 | ||||
| Median | 33 | 30 | |||
| Range | 14-59 | 19-52 | |||
| Bulky tumor ≥10 cm | 11 | 46 | 33 | 65 | .14 |
| Range | 1.3-20 | 5-18 | |||
| Stage IV disease | 3 | 13 | 15 | 29 | .15 |
| LDH >normal | 12 | 50 | 40 | 78 | .017 |
| Extranodal site | 6 | 25 | 27 | 53 | .027 |
| Pleural or pericardial effusion | 5 | 21 | 28 | 55 | .006 |
| ALC cells per µl | 1.01 (0.24-2.15) | .78 | |||
| Median | 0.88 | 1.01 | |||
| Range | 0.3-2.88 | 0.24-2.15 | |||
| Predominant tumor morphology | |||||
| PMBL-like | 8 | 33 | NA | ||
| NSHL-like | 15 | 63 | NA | ||
| Composite (BMBL and NSHL) | 1 | 4 | NA | ||
| IHC | |||||
| CD20+ (malignant cells) | |||||
| First to fourth quartiles | 24/24 | 100 | 51/51 | 100 | 1.0 |
| ≥Fourth quartile | 17/24 | 71 | 51/51 | 100 | <.0001 |
| CD30+ (malignant cells) | 24/24 | 100 | 30/44 | 68 | .001 |
| CD15+ (malignant cells) | |||||
| ≥First quartile | 13/24 | 54 | 2/34 | 6 | <.0001 |
| BCL-6-positive (malignant cells) | 13/15 | 86 | 33/37 | 89 | 1.0 |
| DC-SIGN-positive (bystander cells) | |||||
| ≥1+ staining | 10/19 | 53 | 12/35 | 34 | .25 |
| CD68+ (bystander cells) | |||||
| ≥ 5% staining | 16/16 | 100 | 26/28 | 93 | 1.0 |